Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07891286) titled 'Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults' on Oct. 22.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
LGCMN
Large and Giant Congenital Melanocytic Nevi
NF1
Solid Tumor
Pediatric Tumors
Neurocutaneous Melanocytosis
Congenital Melanocytic Nevus
Arachnoid Cysts
Astrocytoma
Ependymoma
Melanoma
Intervention:
Drug: Mirdametinib
Recruitment Status: Not recruiting
Phase: Pha...